Kategori: Haberler

Nadir Hastalıklar Günü 2023 Kampanyası

Join our campaign for Rare Disease Day! February 28th is Rare Disease Day, where the rare community comes together, finds support and raises awareness for rare diseases across the globe […]

GENERATION HD2 çalışması hakkında Roche/ Genentech güncellemesi

Roche/ Genentech announce that Phase II GENERATION HD2 study is now open. This is great news for the international community since it is planned to run in 15 countries (Argentina, […]

Novartis VIBRANT-HD çalışmasını sonlandırıyor

Novartis shared today the difficult news that they are stopping the VIBRANT-HD study of Branaplam, after some participants devoloping side effects. Read the full Novartis letter Even if this news […]

Uluslararası Huntington Derneği çok cömert bir bağış aldı

International Huntington Association has received a very generous donation. A Norwegian donor is behind the donation. He wishes to remain anonymous. The money is earmarked for a new position at […]

uniQure, AMT-130 denemesinde daha yüksek doz seviyesinde hasta kaydına devam ettiklerini duyurdu

A Message to the Huntington’s Disease Community from uniQure Dear Huntington’s Disease Community Members, This morning, uniQure issued a press release which included an update on our clinical trial ofAMT-130 […]

Wave Life Sciences, Huntington Hastalığında WVE-003 ile Alel-Seçici Hedef Etkileşimini Gösteren İlk Sonuçlarla Faz 1b/2a SELECT-HD Denemesinden Olumlu Güncellemeyi Duyurdu

September 20, 2022 at 7:30 AM EDT PDF Version Single doses of WVE-003 appear generally safe and well-tolerated CSF mutant huntingtin (mHTT) protein was reduced following single doses of 30 […]

uniQure, Huntington Hastalığının Tedavisi için AMT-130 Gen Terapisinin Faz I/II Klinik Çalışmasında Düşük Doz Kohortuna İlişkin Güncellemeyi Duyurdu

~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean reduction of 53.8% of mutant HTT […]

Annexon Biosciences deneme sonuçlarını güncelledi

ANNEXON BIOSCIENCES REPORTS PHASE 2 CLINICAL TRIAL RESULTS DEMONSTRATING UPSTREAM CLASSICAL COMPLEMENT INHIBITION ASSOCIATED WITH CLINICAL BENEFIT IN HUNTINGTON’S DISEASE On June 7, Annexon, that is a clinical-stage biopharmaceutical company […]

Mayıs Farkındalık Ayı Özeti

May Awareness Month 2022 came to an end. Between the webinars, weekends away and Light It Up For HD, there were a lot of initiatives coming from all the different […]

Webinar - Huntington için Keşfet: Dimitri Poffé'nin Latin Amerika Macerası

To finish May Awareness Month in the most inspiring and hopeful way possible, the International Huntington Association and European Huntington Association had a webinar with Dimitri Poffé, a Huntington’s Disease […]